Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 December 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 193 pages)

 

Export 27 results:
Author Title [ Type(Desc)] Year
Filters: Author is de Boer, A.  [Clear All Filters]
Journal Article
M. J. Warnier, Rutten, F. H., Souverein, P. C., de Boer, A., Hoes, A. W., and De Bruin, M. L., Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol, Pharmacoepidemiol Drug Saf, vol. 24, pp. 701-8, 2015.
A. Lalmohamed, Bazelier, M. T., van Staa, T. P., Uitdehaag, B. M., Leufkens, H. G., de Boer, A., and de Vries, F., Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study, Eur J Neurol, vol. 19, pp. 1007-14, 2012.
O. A. Oshagbemi, Franssen, F. M. E., Wouters, E. F. M., van der Zee, A. H. Maitlan, Driessen, J. H. M., de Boer, A., and de Vries, F., C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD, Pulm Pharmacol Ther, p. 101870, 2019.
S. H. Mahmoudpour, Baranova, E. V., Souverein, P. C., Asselbergs, F. W., de Boer, A., and van der Zee, A. H. Maitlan, Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink, Br J Clin Pharmacol, vol. 82, pp. 1647-1659, 2016.
S. Pouwels, Bazelier, M. T., de Boer, A., Weber, W. E., Neef, C. K., Cooper, C., and de Vries, F., Five-year fracture risk estimation in patients with Parkinson's disease, Bone, vol. 56, pp. 266-70, 2013.
S. Pouwels, de Boer, A., Javaid, M. K., Hilton-Jones, D., Verschuuren, J., Cooper, C., Leufkens, H. G., and de Vries, F., Fracture rate in patients with myasthenia gravis: the general practice research database, Osteoporos Int, vol. 24, pp. 467-76, 2013.
B. P. Verhaegh, de Vries, F., Masclee, A. A., Keshavarzian, A., de Boer, A., Souverein, P. C., Pierik, M. J., and Jonkers, D. M., High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors, Aliment Pharmacol Ther, vol. 43, pp. 1004-13, 2016.
A. G. Boef, Souverein, P. C., Vandenbroucke, J. P., A. Vlieg, vanHylckama, de Boer, A., le Cessie, S., and Dekkers, O. M., Instrumental variable analysis as a complementary analysis in studies of adverse effects: venous thromboembolism and second-generation versus third-generation oral contraceptives, Pharmacoepidemiol Drug Saf, vol. 25, pp. 317-24, 2016.
R. G. Duijnhoven, Straus, S. M., Souverein, P. C., de Boer, A., Bosch, J. L., Hoes, A. W., and De Bruin, M. L., Long-term use of 5alpha-reductase inhibitors and the risk of male breast cancer, Cancer Causes Control, vol. 25, pp. 1577-82, 2014.
E. Gieling, de Vries, F., Williams, R., van Onzenoort, H. A. W., de Boer, A., V. Cate, T., Kramers, C., and Burden, A., Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists, Int J Clin Pharm, 2019.
S. H. Mahmoudpour, Asselbergs, F. W., Souverein, P. C., de Boer, A., and van der Zee, A. H. Maitlan, Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: A UK population-based study, Br J Clin Pharmacol, vol. 84, pp. 2365-2372, 2018.
J. P. Yska, van Roon, E. N., de Boer, A., Leufkens, H. G., Wilffert, B., de Heide, L. J., de Vries, F., and Lalmohamed, A., Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery: A Population-Based Cohort Study in the United Kingdom, JAMA Surg, vol. 150, pp. 1126-33, 2015.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., and de Vries, F., Risk of fracture in patients with Charcot-Marie-Tooth disease, Muscle Nerve, vol. 50, pp. 919-24, 2014.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., van Staa, T. P., and de Vries, F., Risk of fracture in patients with Guillain-Barre syndrome, Osteoporos Int, vol. 25, pp. 1845-51, 2014.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., van Onzenoort, H. A., and de Vries, F., Risk of fracture in patients with muscular dystrophies, Osteoporos Int, vol. 25, pp. 509-18, 2014.
S. Pouwels, Bazelier, M. T., de Boer, A., Weber, W. E., Neef, C., Cooper, C., and de Vries, F., Risk of fracture in patients with Parkinson's disease, Osteoporos Int, vol. 24, pp. 2283-90, 2013.
E. M. Gieling, van den Ham, H. A., van Onzenoort, H., Bos, J., Kramers, C., de Boer, A., de Vries, F., and Burden, A. M., Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study, Br J Clin Pharmacol, vol. 83, pp. 1844-1859, 2017.
L. M. Stolk, de Vries, F., Ebbelaar, C., de Boer, A., Schalekamp, T., Souverein, P., A. Cate-Hoek, T., and Burden, A. M., Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants, Br J Clin Pharmacol, vol. 83, pp. 1835-1843, 2017.
J. T. Nielen, Emans, P. J., Dagnelie, P. C., Boonen, A., Lalmohamed, A., de Boer, A., van den Bemt, B. J., and de Vries, F., Severity of Diabetes Mellitus and Total Hip or Knee Replacement: A Population-Based Case-Control Study, Medicine (Baltimore), vol. 95, p. e3739, 2016.
G. J. Lefeber, Koek, H. L., Souverein, P. C., Bouvy, M. L., de Boer, A., and Knol, W., Statins After Myocardial Infarction in the Oldest: A Cohort Study in the Clinical Practice Research Datalink Database, J Am Geriatr Soc, 2019.
H. K. Bronsveld, Peeters, P., de Groot, M. C. H., de Boer, A., Schmidt, M. K., and De Bruin, M. L., Trends in breast cancer incidence among women with type-2 diabetes in British general practice, Prim Care Diabetes, vol. 11, pp. 373-382, 2017.
O. A. Oshagbemi, Keene, S. J., Driessen, J. H. M., Jordan, R., Wouters, E. F. M., de Boer, A., de Vries, F., and Franssen, F. M. E., Trends in moderate and severe exacerbations among COPD patients in the UK from 2005 to 2013, Respir Med, vol. 144, pp. 1-6, 2018.
F. Ahmadizar, Souverein, P., de Boer, A., and van der Zee, A. H. Maitlan, Undertreatment of hypertension and hypercholesterolaemia in children and adolescents with type 1 diabetes: long-term follow-up on time trends in the occurrence of cardiovascular disease, risk factors and medications use, Br J Clin Pharmacol, vol. 84, pp. 776-785, 2018.
W. R. der Zanden, de Vries, F., Lalmohamed, A., Driessen, J. H., de Boer, A., Rohde, G., Neef, C., and C. Heijer, den, Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study, PLoS One, vol. 10, p. e0139367, 2015.
A. Tran-Duy, Connell, N. J., Vanmolkot, F. H., Souverein, P. C., de Wit, N. J., Stehouwer, C. D. A., Hoes, A. W., de Vries, F., and de Boer, A., Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study, J Intern Med, 2018.
A. Tran-Duy, Connell, N. J., Vanmolkot, F. H., Souverein, P. C., de Wit, N. J., Stehouwer, C. D. A., Hoes, A. W., de Vries, F., and de Boer, A., Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study, J Intern Med, vol. 285, pp. 205-214, 2019.
J. T. Nielen, de Vries, F., Dagnelie, P. C., van den Bemt, B. J., Emans, P. J., Lalmohamed, A., de Boer, A., and Boonen, A., Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case-control study, Br J Clin Pharmacol, vol. 81, pp. 370-8, 2016.
[Page last reviewed 6 December 2019]